Masayuki Takeda

Masayuki Takeda

Nara Medical University - Kashihara / Japan
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4993275
奈良県立医科大学
person_outline Masayuki Takeda's MOST POPULAR ARTICLES
1-) Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer K Haratani, H Hayashi, Y Chiba, K Kudo, K Yonesaka, R Kato, H Kaneda, ... JAMA oncology 4 (3), 374-378, 2018 7452018
2-) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, ... Science translational medicine 3 (99), 99ra86-99ra86, 2011 6482011
3-) Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment K Haratani, H Hayashi, T Tanaka, H Kaneda, Y Togashi, K Sakai, ... Annals of oncology 28 (7), 1532-1539, 2017 2612017
4-) First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trialLG Paz-Ares, SS Ramalingam, TE Ciuleanu, JS Lee, L Urban, RB Caro, ...Journal of Thoracic Oncology 17 (2), 289-308, 20222692022
5-) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open …V Subbiah, J Wolf, B Konda, H Kang, A Spira, J Weiss, M Takeda, Y Ohe, ...The Lancet Oncology 23 (10), 1261-1273, 20222672022